Michael J. Morris

Michael J. Morris, MD is Prostate Cancer Section Head in the Genitourinary Oncology Service and Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. Dr. Morris is internationally recognized as the leading clinical investigator of PSMA-targeted radioligand therapy in prostate cancer, having been the principal U.S. investigator and steering committee chair for the landmark VISION trial (NEJM 2021), which led to the FDA approval of lutetium-177-PSMA-617 (Pluvicto, 177Lu-PSMA-617) for mCRPC in March 2022 — representing the most significant new treatment modality for prostate cancer in nearly a decade. VISION randomized 831 patients with PSMA-positive mCRPC to 177Lu-PSMA-617 plus standard of care versus standard of care alone, demonstrating significant improvements in rPFS (HR 0.40; p<0.001) and OS (HR 0.62; p<0.001). Beyond VISION, Dr. Morris has been a leader in the broader theranostic field, conducting research on PSMA PET imaging for patient selection and response assessment, combination strategies of 177Lu-PSMA with PARP inhibitors and AR-targeted agents, and the clinical utility of alpha-emitter PSMA-targeted agents (actinium-225-PSMA-617). He has also made foundational contributions to prostate cancer clinical trial design, co-leading FDA qualification of PSA doubling time and circulating tumor cell endpoints, and has been a key investigator in the ALSYMPCA trial of radium-223. Dr. Morris serves on NCCN and ASCO guideline committees for prostate cancer.